Pharmaceuticals

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

A new alliance in healthcare marketing merges pharmaceutical expertise with provider-side insights, leveraging AI and big data to fix a fragmented system.

Adial Pharmaceuticals files a key patent to protect its personalized Alcohol Use Disorder drug, AD04, until 2045, signaling a new era for addiction medicine.

A new AI solution promises to automate a critical manufacturing step, tackling costly errors and downtime that plague the life sciences industry.

With new data showing six-month efficacy and a unique liquid formula, Galderma's Relfydess is poised to challenge established players in the neuromodulator space.

A coalition of top GOP senators and state attorneys general is urging the FDA to pull mifepristone, escalating the fight over abortion to the federal level.

AstraZeneca's acquisition of Modella AI signals a major shift, embedding advanced AI directly into its cancer research to accelerate new treatments.

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

Moving beyond hype, ArisGlobal's record growth and enterprise adoption of its NavaX AI show the pharmaceutical industry is now operationalizing AI at scale.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Kye Pharma brings SLENYTO®, a first-of-its-kind prescription sleep aid, to Canada, offering relief to children with ASD and SMS and their families.

As regulations tighten, Americhem unveils new polymers designed to help medical device makers navigate PFAS bans and enhance device traceability.

A new partnership aims to tackle the growing global health crisis of invasive fungal infections, a silent killer claiming millions of lives annually.

The first-ever Wegovy pill is now available via telehealth platform Ro, offering a cash-pay option that could revolutionize access to weight loss drugs.

Aptar's 'Beat the Blink' technology, in partnership with Bausch + Lomb, promises to solve the age-old problem of inaccurate eye drop dosing.

As Disc Medicine nears a potential drug launch, its new HR chief hire reveals a critical strategy for navigating biotech's intense talent wars.